Literature DB >> 8971472

Targets for cancer therapy in the cell cycle pathway.

R N Rao1.   

Abstract

Progression through the cell cycle is a complex process that is regulated at many levels by several proteins. We are just beginning to understand how these proteins accomplish this regulation. The p16-cyclin D1.cdk4-pRb pathway is one of the most important pathways, which is altered in a majority of cancers of different types. This review focuses on some of the proteins in this pathway that offer new opportunities for drug discovery. Some guidelines to evaluate the relevance of these proteins as targets for cancer therapy and the importance of developing a combination therapy targeting multiple pathways are also discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971472     DOI: 10.1097/00001622-199611000-00012

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  3 in total

1.  TTD: Therapeutic Target Database.

Authors:  X Chen; Z L Ji; Y Z Chen
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.

Authors:  Karen A Rossi; Jay A Markwalder; Steven P Seitz; Chong-Hwan Chang; Sarah Cox; Michael D Boisclair; Leonardo Brizuela; Stephen L Brenner; Pieter F W Stouten
Journal:  J Comput Aided Mol Des       Date:  2005-02       Impact factor: 3.686

3.  Neoplastic transformation-associated stimulation of the in vitro resolution of concatemer junction fragments from minute virus of mice DNA.

Authors:  G Kuntz-Simon; T Bashir; J Rommelaere; K Willwand
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.